HDL Map (with apoA-I)

For more than forty years, total circulating HDL cholesterol (HDL-C) has been used as a primary indicator of cardiovascular disease (CVD) risk. However, HDL is comprised of subpopulations of different sizes, composition and characteristics that impact cardiovascular risk in drastically different ways.

 Data from the Framingham Heart Study, Framingham Offspring Study, Veterans Affairs HDL Cholesterol Intervention Trial (VA-HIT) and HDL-Atherosclerosis Treatment Study (HATS) have shown that HDL subpopulations are significantly better predictors of CVD risk than HDL-C values alone.

 The Boston Heart HDL Map® is the only test available that quantifies the amount of apoA-I in the five most significant subpopulations, resulting in a deeper understanding of a patient’s CVD risk. This exclusive method provides healthcare providers with an accurate and consistent indication of reverse cholesterol transport by separating the larger, cardioprotective particles most associated with decreased CVD risk from the smaller HDL particles associated with increased risk. Healthcare providers can use this information to determine the most effective treatment strategy, as well as monitor response to therapy.

Freeze the provided ice packs for 24 hours before your blood draw.

Fast for 8-12 hours before your blood draw. You may drink only water, black coffee, or tea without dairy or sugar.

Hydrate before your blood draw.